2025 Volume 14 Issue 3 Pages 121-129
Chimeric antigen receptor (CAR)-engineered T-cell therapy can induce a high remission rate for B-cell tumors and multiple myeloma. However, a significant number of patients experience a relapse after a transient response. To improve the efficacy of CAR-T cell therapy, genetic modification focused on epigenetic factors and cytokine signaling has been actively explored to confer long-lived potential and resistance to exhaustion of CAR-T cells. Studies are also underway to prevent or mitigate therapeutic toxicities, such as cytokine release syndrome, which inevitably increase in proportion to the therapeutic effect. In addition, the risk of developing T-cell malignancies after CAR T-cell therapy is better understood, and there is increasing interest in the long-term safety of the therapy. Here, I will review recent studies and future directions in CAR T-cell therapy with respect to the above perspectives.
